Skip to main content
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.

Morphine

Morphine molecule structureMorphine molecule structure
Morphine
M, Miss Emma, Morpho, Dreamer, White Stuff
Psychoactive Class
Chemical Class

Morphine is the principal alkaloid of the opium poppy (Papaver somniferum)citation needed and the prototypical opioid analgesic.1 First isolated by Friedrich Sertürner in 1805,2 it has served as the foundation from which numerous semi-synthetic opioids have been derived. Morphine produces potent analgesia,3 euphoria,3 and sedation,3 and is used clinically for the management of moderate to severe pain.3 Its use carries significant risks of tolerance, physical dependence,4 and abuse.4

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~5 mg
Light5-10 mg
Moderate10-20 mg
Strong20-30 mg
Heavy30+ mg
Bioavailability
40-50%

Duration

Onset10-30 minutes
Come Up20-40 minutes
Peak2-3 hours
Offset1-3 hours
After Effects2-6 hours
Total4-6 hours
Half-life
2-3 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Forked from Subjective Effect Documentation work byJosie Kins August 2016.

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)
white → red2 → purple1
Mecke(ME)
white → blue2 → green2
Mandelin(MD)
yellow2 → black2
Liebermann(LB)
white → blue2 → blue3 → black3
Powered by PROtestkit.eu

Pharmacology

Pharmacodynamics

Morphine acts primarily as an agonist at the μ-opioid receptor (MOR), which mediates its principal pharmacological effects.citation needed Its intrinsic activity at the MOR is context-dependent; it functions as a full agonist under some assay and tissue conditions while behaving as a partial agonist or antagonist in others. Morphine also activates κ-opioid and δ-opioid receptors, and interacts predominantly with the μ–δ-opioid receptor heteromer. Peripherally, it acts on μ-opioid receptors expressed in the myenteric plexus of the gastrointestinal tract, reducing gut motility.3

Pharmacokinetics

Morphine undergoes extensive first-pass metabolism in the liver, resulting in an oral bioavailability of approximately 40 to 50%.citation needed It is approximately 35% protein bound with a volume of distribution of 5.31 L/kg. Metabolism occurs primarily via glucuronidation by UGT2B7 at the 3 and 6 positions, predominantly in the liver with minor contributions from the brain and kidneys. The major metabolite, morphine-3-glucuronide (approximately 60% of a dose), is pharmacologically inactive, while morphine-6-glucuronide (6 to 10% of a dose) is an active metabolite that retains μ-opioid receptor affinity and is estimated to account for approximately 85% of the observed pharmacological response. The elimination half-life is approximately 2 to 3 hours, and roughly 87% of a dose is excreted renally within 72 hours, with 2 to 10% recovered as unchanged morphine.

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AlcoholBenzodiazepinesCocaineDXMGHB/GBLKetamineMXEPregabalinTramadol

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

AmphetaminesMAOIsMephedroneNitrous oxidePCP
Powered by TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
Tolerance develops rapidly with repeated use, sometimes after only a short period of consumption. This necessitates progressively higher doses to achieve the same effects.
Cross Tolerance

Opioids (μ-opioid receptor agonists)

Baseline Reset
After a period of abstinence, tolerance decreases significantly. Users returning to the substance after abstinence should use substantially lower doses than their pre-abstinence amounts, as their previous typical dose may produce life-threatening effects.

Harm Potential

Addiction & Dependence

Psychological

Extremely High

Morphine is ranked among the most addictive substances known, with studies placing it alongside heroin as the most addictive drug. Psychological dependence is complex and protracted, persisting long after physical withdrawal resolves.citation needed Relapse rates are estimated as high as 98%, and users commonly experience severe depression, anxiety, and overwhelming drug craving during recovery.

Physical

Extremely High

Physical dependence develops readily with repeated administration, sometimes after only a short period of use. Withdrawal produces the prototypical opioid withdrawal syndrome with symptoms including anxiety, perspiration, muscle aches, severe cramping, diarrhea, vomiting, and intense drug craving progressing through distinct stages over 7-12 days.citation needed While withdrawal is not typically fatal in otherwise healthy individuals, it is intensely uncomfortable.

Toxicity

Gastrointestinal

Constipation is one of the most common side effects, occurring consistently even at typical therapeutic doses due to reduced gut motility.citation needed

Endocrine

Chronic use causes hypogonadism and hormone imbalances in the majority of long-term users of both sexes; studies suggest up to 90% of chronic opioid users experience opioid-induced hypogonadism.

Immune System

Chronic use may suppress immune function and increase susceptibility to infections including pneumonia, tuberculosis, and HIV/AIDS; this immunosuppressive effect is primarily documented in individuals with opioid addiction.citation needed

Central Nervous System

Excess consumption over time can cause changes in synaptic neuroplasticity; these effects are associated with chronic heavy use rather than occasional administration.citation needed

Psychosis Risk

Confusion, nightmares, and hallucinations may occur as side effects, though these are not prominently reported at typical doses.

History & Culture

Ancient and Early Use

The history of morphine is deeply intertwined with humanity's long relationship with the opium poppy. The earliest documented references to opium-based preparations can be traced to the 3rd century BC, when the Greek philosopher Theophrastus recorded their existence.6 Some

Legality

By Country

Illegal11
Austria flagAustriaIllegal
Belgium flagBelgiumIllegal
Brazil flagBrazilIllegal
Finland flagFinlandIllegal
India flagIndiaIllegal
Indonesia flagIndonesiaIllegal
Netherlands flagNetherlandsIllegal
New Zealand flagNew ZealandIllegal
Singapore flagSingaporeIllegal
Sweden flagSwedenIllegal
Thailand flagThailandIllegal
Prescription3
United States flagUnited StatesPrescription only
Mexico flagMexicoPrescription only
United Kingdom flagUnited KingdomPrescription only
Legal / decriminalized2
Australia flagAustraliaLegal (regulated)
Colombia flagColombiaLegal (regulated)

References

Source Pages

  1. Drug Users Bible by Dominic Milton Trott
  2. DrugBank
  3. DrugBank: Morphine salt
  4. DrugBank: Morphine-6-glucuronide
  5. Erowid: Morphine Vault
  6. Erowid: Opioid FAQ
  7. PsychonautWiki: Morphine
  8. The Drug Classroom
  9. TripSit: Drug Combinations
  10. Wikipedia

Citations

  1. Morphine. Medical Subject Headings (MeSH) (n.d.). https://www.ncbi.nlm.nih.gov/mesh/680090201
  2. The isolation of morphine by Serturner. Journal of Anaesthesiology Clinical Pharmacology (2016). https://pmc.ncbi.nlm.nih.gov/articles/PMC5125194/1
  3. Morphine. StatPearls (n.d.). https://www.ncbi.nlm.nih.gov/books/NBK526115/12345
  4. MORPHINE SULFATE oral solution, CII — Prescribing Information. DailyMed (NIH) (n.d.). https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4d425667-006b-446d-832c-63040509ad59&type=display12
  5. Reddy RG, Aung T, Karavitaki N, & Wass JA. (2010). Opioid-induced hypogonadism. BMJ, 341, c4462. https://doi.org/10.1136/bmj.c446212
  6. Svend Norn, Poul R Kruse, & Edith Kruse. (2005). [History of opium poppy and morphine]. Dansk Medicinhistorisk Arbog, 33, 171–184. https://pubmed.ncbi.nlm.nih.gov/17152761/12
  7. Heroin: Killer Drug was Marketed and Sold by Bayer as a Non-Addictive Cough Syrup. Ancient Origins (n.d.). https://www.ancient-origins.net/history-important-events/heroin-marketed-bayer-00112121
  8. From the Archives: UR's Gates Gave Morphine Its Structure. Campus Times (n.d.). https://www.campustimes.org/2019/04/29/from-the-archives-urs-gates-gave-morphine-structure/1
  9. Life-work of János Kabay, founder of the Alkaloida pharmaceutical factory. Collection of Hungarikums (n.d.). https://www.hungarikum.hu/en/content/life-work-j%C3%A1nos-kabay-founder-alkaloida-pharmaceutical-factory1
  10. Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2026L00633/latest/text1

Further Reading

  1. Christrup 1997: Morphine metabolites (DOI)
  2. Holmquist 2009: Opioid metabolism and CYP450 (DOI)
  3. Schmidt et al. 2002: Receptor binding affinities (DOI)

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Lyrea avatar
    Step 2 · First-pass review

    A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes8 human edits · latest

Times are UTCNewest first

15 August 2026

  1. Lyrea · Updated the article

  2. Lyrea · Updated the article

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Morphine article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.